This HTML5 document contains 40 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05448/identifier/pubchem-compound/
n8http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB05448/identifier/drugbank/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05448/identifier/chemspider/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB05448
rdf:type
n3:Drug
n3:description
PX-12 (1-methylpropyl 2-imidazolyl disulfide) is a small-molecule inhibitor of Trx-1 (thioredoxin-1), stimulates apoptosis, down-regulates HIF-1α and vascular endothelial growth factor (VEGF) and inhibits tumor growth in animal models. Since high levels of Trx-1 have been associated with colorectal, gastric and lung cancers, PX-12 is indicated as a potential cancer treatment in combination with chemotherapy for patients with advanced metastatic cancer. Initial trials correlated doses of Px-12 with increased patient survival.
n3:generalReferences
# Jordan BF, Runquist M, Raghunand N, Gillies RJ, Tate WR, Powis G, Baker AF: The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):529-36. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15701837 # Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Jun;29(5):359-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17805439 # Ramanathan RK, Kirkpatrick DL, Belani CP, Friedland D, Green SB, Chow HH, Cordova CA, Stratton SP, Sharlow ER, Baker A, Dragovich T: A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors. Clin Cancer Res. 2007 Apr 1;13(7):2109-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17404093 # Galmarini CM: Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer. Curr Opin Investig Drugs. 2006 Dec;7(12):1108-15. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17209529 # Kiviharju K, Moilanen U, Leisola M, Eerikainen T: A chemostat study of Streptomyces peucetius var. caesius N47. Appl Microbiol Biotechnol. 2007 Jan;73(6):1267-74. Epub 2006 Nov 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17115210 # Baker AF, Dragovich T, Tate WR, Ramanathan RK, Roe D, Hsu CH, Kirkpatrick DL, Powis G: The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med. 2006 Feb;147(2):83-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16459166 # Bayes M, Rabasseda X, Prous JR: Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15148527 # Bergink AP, van Meurs JB, Loughlin J, Arp PP, Fang Y, Hofman A, van Leeuwen JP, van Duijn CM, Uitterlinden AG, Pols HA: Estrogen receptor alpha gene haplotype is associated with radiographic osteoarthritis of the knee in elderly men and women. Arthritis Rheum. 2003 Jul;48(7):1913-22. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12847685 # Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G: The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol Cancer Ther. 2003 Mar;2(3):235-43. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12657718 # Husbeck B, Powis G: The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF-7 human breast cancer cells. Carcinogenesis. 2002 Oct;23(10):1625-30. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12376470
n3:group
investigational
n3:indication
Investigated for use/treatment in cancer/tumors (unspecified), gastric cancer, and pancreatic cancer.
owl:sameAs
n8:DB05448
dcterms:title
PX-12
adms:identifier
n6:189920 n9:DB05448 n11:219104
n3:mechanismOfAction
PX-12 irreversibly inhibits the redox protein thioredoxin, which has been associated with cancer and tumor growth.
n3:synonym
1-methylpropyl 2-imidazolyl disulfide
n3:toxicity
Doses of PX-12 up to 226 mg/m2 were shown to be well tolerated and had minimal toxicity
n3:IUPAC-Name
n4:271B43FA-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B4400-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B43FF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B43FC-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B43FD-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B43FE-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B43F8-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B43F9-363D-11E5-9242-09173F13E4C5 n4:271B43F6-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B43F7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4406-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4407-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4401-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4402-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4404-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4403-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4405-363D-11E5-9242-09173F13E4C5
n3:absorption
the optimum PD dose was identified as 96 mg/m2 as a 3-hr infusion
n3:Bioavailability
n4:271B440C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B440E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B440F-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B440B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B440A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B440D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B43FB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4408-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4409-363D-11E5-9242-09173F13E4C5